Coromandel International Board Approves Unaudited Financial Results for Q1 FY27

Coromandel International Limited announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved standalone and consolidated results, alongside key strategic decisions including the conversion of loan value to equity in its subsidiary and restructuring of loans for a step-down subsidiary. The company also disclosed its segment reporting and received an unmodified limited review report from its auditors.

Coromandel International Reports Q1 FY27 Financial Outcomes

Coromandel International Limited’s Board of Directors convened on July 23, 2026, to review and approve the company’s unaudited financial results for the first quarter ended June 30, 2026. This includes both standalone and consolidated financial statements. The Audit Committee had previously recommended these results at their meeting held on the same day.

Key Financial Highlights

For the quarter ended June 30, 2026, Coromandel International reported a revenue from operations of ₹7,743.55 Crores on a standalone basis and ₹8,164.77 Crores on a consolidated basis. The net profit after tax for the quarter stood at ₹376.96 Crores (standalone) and ₹381.56 Crores (consolidated).

Strategic Business Decisions

The Board also approved significant strategic moves. Firstly, the conversion of a loan amounting to approximately ₹108 Crores into equity shares for Coromandel Chemicals Limited, a wholly-owned subsidiary. Secondly, the restructuring of loans worth USD 9.70 Million granted to Baobab Mining and Chemicals Corporation S A (BMCC), a step-down subsidiary, into equity or preference shares.

Segment Performance

The company’s reporting indicates continued focus on its two main business segments: Nutrient & other allied business and Crop protection. Segment revenue from operations for the quarter was ₹7,743.55 Crores (standalone) and ₹8,164.77 Crores (consolidated). Segment profit before tax was ₹505.34 Crores (standalone) and ₹513.68 Crores (consolidated).

Auditor’s Review

The unaudited financial results, both standalone and consolidated, were accompanied by a Limited Review Report from M/s. S R Batliboi & Associates LLP, Chartered Accountants. The auditors stated that based on their review, nothing had come to their attention that would suggest the statements were not prepared in accordance with the applicable accounting standards and regulations, and that they did not contain any material misstatement.

Source: BSE

Previous Article

Eris Lifesciences Board Meeting Scheduled for July 29, 2026, to Approve Q1 FY27 Financial Results